Neoadjuvant Goserelin for Triple Negative Breast Cancer
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a phase II randomized trial that will evaluate the effect of adding LHRH analogue,
goserelin, to the standard neoadjuvant chemotherapy to patients with triple negative breast
cancer. Targeting LHRH might decrease resistance to chemotherapeutic agents in the
neoadjuvant setting and increases clinical and pathological response rates. Additionally,
exploring potential surrogate markers (as AR and LHRH receptors) for molecular distinct
subtypes of TNBC.